MOMO'S BREAKOUT BOARD

[dirkv]

Jaguar Health (jagx) : 0.1439 – 4.83%

Time for a strong recovery
https://www.sec.gov/Archives/edgar/data/1462830/000156761923007925/doc1.htm
Shares Outstanding 50.76M
Implied Shares Outstanding 50.76M
Float 40.68M

https://jaguar.health/pipeline/


Jan 03, 2024 0.1505 0.1538 0.1310 0.1439 0.1439 3,672,347
Jan 02, 2024 0.1520 0.1560 0.1510 0.1510 0.1510 3,847,200
Dec 29, 2023 0.1640 0.1700 0.1500 0.1510 0.1510 4,813,700
Dec 28, 2023 0.1670 0.1680 0.1610 0.1620 0.1620 2,962,900
Dec 27, 2023 0.1720 0.1720 0.1590 0.1630 0.1630 3,800,700
Dec 26, 2023 0.1700 0.1750 0.1660 0.1720 0.1720 2,583,600
Dec 22, 2023 0.1550 0.1680 0.1540 0.1670 0.1670 4,743,000
Dec 21, 2023 0.1540 0.1550 0.1500 0.1530 0.1530 2,175,200
Dec 20, 2023 0.1560 0.1570 0.1460 0.1500 0.1500 4,123,200
Dec 19, 2023 0.1600 0.1680 0.1550 0.1620 0.1620 3,909,500
Dec 18, 2023 0.1650 0.1680 0.1500 0.1550 0.1550 4,216,500
Dec 15, 2023 0.1680 0.1900 0.1600 0.1600 0.1600 8,481,100
Dec 14, 2023 0.1550 0.1700 0.1540 0.1670 0.1670 4,522,300
Dec 13, 2023 0.1610 0.1610 0.1510 0.1530 0.1530 6,719,900
Dec 12, 2023 0.1880 0.1900 0.1680 0.1690 0.1690 4,945,700
Dec 11, 2023 0.2250 0.2290 0.1700 0.1830 0.1830 14,068,500
Dec 08, 2023 0.2890 0.2890 0.2650 0.2650 0.2650 2,691,000
Dec 07, 2023 0.3150 0.3190 0.2860 0.2880 0.2880 4,557,500
Dec 06, 2023 0.3240 0.3300 0.3160 0.3200 0.3200 3,074,500
Dec 05, 2023 0.3800 0.3800 0.3100 0.3240 0.3240 8,376,900
Dec 04, 2023 0.3500 0.4050 0.3420 0.3900 0.3900 9,457,200
Dec 01, 2023 0.3560 0.3600 0.3470 0.3560 0.3560 5,757,900
Nov 30, 2023 0.3570 0.3830 0.3470 0.3540 0.3540 2,080,300
Nov 29, 2023 0.3460 0.3700 0.3430 0.3500 0.3500 1,866,800
Nov 28, 2023 0.3300 0.3530 0.2910 0.3490 0.3490 2,643,600
Nov 27, 2023 0.3600 0.3600 0.3420 0.3500 0.3500 2,798,900
Nov 24, 2023 0.3500 0.3760 0.3410 0.3740 0.3740 2,158,200
Nov 22, 2023 0.3600 0.3670 0.3300 0.3430 0.3430 3,410,800
Nov 21, 2023 0.3740 0.4000 0.3390 0.3470 0.3470 11,863,800
Nov 20, 2023 0.4250 0.5140 0.4130 0.4620 0.4620 12,583,000


Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.

https://jaguar.health

Full Time Employees: 60